Halozyme Therapeutics Inc. Common Stock vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.34 (market cap $12.58B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.65 (market cap $1.96B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 6.4× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| HALO | SOXS | |
|---|---|---|
Market Cap | $12.58B | $1.96B |
Volume | 2,179,278 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $115.22 | $988.00 |
52-Week Low | $61.63 | $29.62 |
Typical Hold Time | 1 Days | 11 Days |
Enterprise Value | $14.49B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $34.53, up 12.68% with a bearish technical signal. The fund provides inverse leveraged exposure to semiconductor stocks, making it highly volatile and suitable for short-term tactical trades rather than long-term investment. Recent performance reflects semiconductor sector weakness, with technical indicators showing mixed signals but overall bearish momentum.
The outlook remains challenging as SOXS faces structural headwinds from persistent AI hardware demand and semiconductor industry strength. Investment opportunities exist for tactical bearish bets during sector pullbacks, but risks include high volatility, decay from daily rebalancing, and potential for rapid losses if semiconductor stocks rebound. The fund is best suited for experienced traders with short-term horizons.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →